Roseburia intestinalis

Roseburia intestinalis is a next-generation probiotic bacterium that produces butyrate through fermentation of dietary fiber in the colon. This butyrate production supports intestinal barrier function, reduces inflammation, and promotes optimal digestive health.

Origin & History

Roseburia intestinalis is a gram-positive, anaerobic bacterium prevalent in the human gut. It is cultured under anaerobic conditions due to its oxygen sensitivity, often isolated from fecal samples for research purposes.

Historical & Cultural Context

Identified in the late 20th century, Roseburia intestinalis has gained attention for its role in maintaining gut health and its potential therapeutic applications.

Health Benefits

- Produces butyrate, promoting colon health and reducing inflammation, which is vital for digestive comfort. - Supports digestion by breaking down complex carbohydrates, enhancing nutrient absorption and energy levels. - Enhances immune function by increasing the production of anti-inflammatory cytokines, reducing the risk of infections. - Promotes mental well-being by influencing the gut-brain axis, potentially alleviating anxiety and depression. - Aids in weight management by regulating fat storage and energy expenditure, supporting a healthy body weight. - Improves skin health by reducing systemic inflammation, which can alleviate conditions like acne and eczema. - Supports cardiovascular health by reducing cholesterol levels, lowering the risk of heart disease.

How It Works

Roseburia intestinalis ferments complex carbohydrates and resistant starches through butyrate-CoA transferase pathways, producing short-chain fatty acids, particularly butyrate. Butyrate activates GPR43 and GPR109A receptors on colonocytes, strengthening tight junctions and reducing NF-κB inflammatory signaling. This mechanism enhances intestinal barrier integrity while promoting regulatory T-cell differentiation through histone deacetylase inhibition.

Scientific Research

Research on Roseburia intestinalis includes in vitro studies and animal models, with growing interest in its role in gut health and metabolic regulation. Human trials are limited but promising.

Clinical Summary

Research on Roseburia intestinalis primarily consists of observational studies and in vitro experiments rather than randomized controlled trials. Studies show depleted levels in inflammatory bowel disease patients and metabolic disorders, with butyrate concentrations reaching 10-20 mM in healthy individuals. Small pilot studies suggest supplementation may increase fecal butyrate levels by 2-3 fold within 2-4 weeks. Evidence remains preliminary, requiring larger clinical trials to establish therapeutic efficacy and optimal dosing protocols.

Nutritional Profile

- Produces butyrate and other short-chain fatty acids. - Contains enzymes that degrade complex carbohydrates. - Rich in polysaccharides beneficial for gut health.

Preparation & Dosage

There is no standardized dosage for Roseburia intestinalis supplements. Consult a healthcare provider before use.

Synergy & Pairings

Prebiotic Fiber,Polyphenols,Omega-3 Fatty Acids

Safety & Interactions

Roseburia intestinalis appears generally safe for healthy individuals, though comprehensive safety data is limited due to its recent classification as a next-generation probiotic. Mild gastrointestinal symptoms including bloating or gas may occur during initial colonization. No significant drug interactions are currently documented, but caution is advised with immunosuppressive medications. Safety during pregnancy and lactation has not been established, requiring medical supervision for use in these populations.